Unaudited NAV for December 2022
Arix Bioscience PLC (ARIX)
Unaudited NAV for December 2022
30-Jan-2023 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Unaudited NAV for December 2022
LONDON, 30 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 December 2022 as follows:
Date
NAV Breakdown
Total NAV
NAV per share
Listed Portfolio
Unlisted Portfolio
Cash
Other Interests
31 December 2022
(unaudited)
£47.0m
£56.2m
£123.4m
£3.0m
£229.6m
£1.78
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
ISIN: GB00BD045071 Category Code: NAV TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 219090 EQS News ID: 1545893
End of Announcement EQS News Service